Jason Laday

Oral brepocitinib failed to meet its primary endpoint in a phase 2 trial of adults with moderate to severe lupus, according to a press release from the manufacturer.The study aimed to assess brepocitinib (Priovant Therapeutics) based on the primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at week 52. In a statement, Priovant, which holds the drug’s global

SAN DIEGO — Shortness of breath, male sex, age and elevated inflammatory markers are all more predictive of new interstitial lung disease in systemic sclerosis than disease duration, according to data presented at ACR Convergence 2023.“ILD is associated with morbidity and mortality in patients with systemic sclerosis,” Liubov Petelytska, MD, PhD, of University Hospital Zurich,

The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an inadequate response to, or cannot taper, corticosteroids, according to a press release from Sanofi.

PHILADELPHIA — Combination therapy with celecoxib plus golimumab failed to show significant superiority to golimumab alone in slowing spine damage in radiographic axial spondyloarthritis, according to data presented at ACR Convergence 2022.“The reduction of clinical burden and prevention of disability can probably be best achieved by early and adequate treatment targeting both

The FDA has granted an orphan drug designation for biotherapeutics firm aTyr’s potential first-in-class immunomodulator efzofitimod in the treatment of systemic sclerosis, according to a company press release.

Older children and those with ferritin levels greater than 500 µg/L are at highest risk for severe multisystem inflammatory syndrome in children resulting in ICU admission after COVID-19, according to data published in CMAJ.

Iberdomide, a novel oral cereblon modulator, was superior to a placebo only in patients with systemic lupus erythematosus who received the highest dose in a phase 2 trial, albeit with a high incidence of adverse events, according to data.

The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant. In a statement released March 25, the FDA said it was limiting the use of sotrovimab (Xevudy, GlaxoSmithKline) in some U.S. regions, mos…

The FDA has granted a prior approval supplement to Zydus Lifesciences Limited allowing the company to market its generic mycophenolate mofetil injection USP, 500 mg vial, following a transfer to a new manufacturing site.According to a press release from Zydus, formerly known as Cadila Healthcare Ltd…

Autoimmune treatments accounted for more than half of all specialty drug use in 2021, according to a drug trend report released by CVS Health.